Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

1

Infections are a leading cause of non-relapse mortality following CAR T-cell therapy, highlighting the need for effective vaccination strategies.
2

Patients receiving CAR T-cell therapy exhibit distinct humoral deficiencies, particularly between CD19 and BCMA-targeted therapies.
3

Vaccination response rates post CAR T-cell therapy are low, with only 27-35% responding to COVID-19 mRNA vaccines and 35% to influenza vaccines.
4

BCMA CAR T-cell recipients show poorer seroprotection rates against vaccine-preventable infections compared to CD19 CAR T-cell recipients.
5

The study aims to assess humoral immunity and vaccine responses to 12 vaccine-preventable infections in CAR T-cell therapy patients.

Blood Cancer Journal

by Sigrun Einarsdottir, Stephanie Lobaugh, Danny Luan, Marina Gomez-Llobell, Padmapriya Subramanian, Sean Devlin, David Chung, Parastoo B. Dahi, Lorenzo Falchi, Sergio Giralt, Heather Landau, Alexander M. Lesokhin, Richard Lin, Jennifer Lue, Sham Mailankody, M. Lia Palomba, Jae H. Park, Gilles Salles, Michael Scordo, Silvia Escribano-Serrat, Jaime Sanz, Kai Rejeski, Roni Shouval, Saad Usmani, Miguel-Angel Perales, Gunjan Shah, Zainab Shahid
July 2, 2025

1